logo

For the Inventor, By the Inventor

Fort Washington, PA, United States of America

Vitae Pharmaceuticals, Inc.

Calculating rank
USPTO Granted Patents = 85

% Expired Patents = 37.6



Trademarks = 3

Forward Citations = 374

Loading Chart...
Loading Chart...

62 inventors (with patents filed for the assignee):

goldMedal Suresh B Singh (67 out of 74 patents)

silverMedal David A Claremon (58 out of 147 patents)

bronzeMedal Linghang Zhuang (54 out of 65 patents)

4.  Colin M Tice (53 out of 68 patents)

5.  Wei Zhao (41 out of 53 patents)

6.  Jing Yuan (40 out of 57 patents)

7.  Lawrence Wayne Dillard (38 out of 64 patents)

8.  Yajun Zheng (33 out of 38 patents)

9.  Zhenrong Xu (32 out of 38 patents)

10.  Salvacion Cacatian (32 out of 33 patents)

11.  Lanqi Jia (30 out of 31 patents)

12.  Yi Fan (26 out of 28 patents)

13.  Stephen D Lotesta (26 out of 26 patents)

14.  Katerina Leftheris (26 out of 90 patents)

15.  Yuanjie Ye (24 out of 25 patents)


Core Competencies:
ROR-Gamma
Beta-Secretase
Hydroxysteroid Dehydrogenase
Dihydropyrrolopyridine
Inhibitors
Modulators
Piperidine
Carbamate
Urea
Liver X Receptor
Menin-MLL
Isoindoline

85 patents:

1. 12312359 - Inhibitors of the menin-MLL interaction (2025-05-27),
2. 11919901 - Inhibitors of the menin-MLL interaction (2024-03-05),
3. 11739085 - Inhibitors of the menin-MLL interaction (2023-08-29),
4. 11535614 - Dihydropyrrolopyridine inhibitors of ROR-gamma (2022-12-27),
5. 11479557 - Inhibitors of the menin-MLL interaction (2022-10-25),
6. 11186573 - Inhibitors of ROR gamma (2021-11-30),
7. 11008340 - Modulators of ROR-gamma (2021-05-18),
8. 11001583 - Dihydropyrrolopyridine inhibitors of ROR-gamma (2021-05-11),
9. 10899758 - Inhibitors of the menin-MLL interaction (2021-01-26),
10. 10829481 - Benzimidazole derivatives as modulators of ROR-gamma (2020-11-10),
11. 10829448 - Substituted benzoimidazoles as modulators of ROR-γ (2020-11-10),
12. 10807980 - Dihydropyrrolopyridine inhibitors of ROR-gamma (2020-10-20),
13. 10683302 - Inhibitors of the menin-MLL interaction (2020-06-16),
14. 10399976 - Dihydropyrrolopyridine inhibitors of ROR-gamma (2019-09-03),
15. 10336717 - Inhibitors of beta-secretase (2019-07-02),
Company Overview
Vitae Pharmaceuticals, Inc., based in Fort Washington, PA, specializes in the development of innovative therapeutics targeting ROR-Gamma modulators. The company focuses on advancing treatments through its expertise in various core technologies, including beta-secretase and hydroxysteroid dehydrogenase inhibitors. Vitae is committed to addressing unmet medical needs by leveraging its knowledge in dihydropyrrolopyridine and piperidine compounds, positioning itself at the forefront of pharmaceutical research and development.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 27 2026

Vitae Pharmaceuticals, Inc. USPTO Patent Assignee Logo
85 Patents

#4 in Fort Washington, PA

#167 in Pennsylvania

#4,380 in US

#8,970 in the World

Fort Washington, PA (US)
Fort Washington, PA, United States of America

Vitae Pharmaceuticals, Inc.

Forward Citations = 374

62 inventors:

goldMedal Suresh B Singh (67 out of 74 patents)

silverMedal David A Claremon (58 out of 147 patents)

bronzeMedal Linghang Zhuang (54 out of 65 patents)

4.  Colin M Tice (53 out of 68 patents)

5.  Wei Zhao (41 out of 53 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Vitae Pharmaceuticals, Inc.. Retrieved from https://idiyas.com/company/vitae-pharmaceuticals

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…